ReviewJournal of clinical medicine2021
The Role of Myeloid-Derived Suppressor Cells (MDSCs) in Graft-versus-Host Disease (GVHD).
Review in Journal of clinical medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 33 citations in OpenAlex.
- Early high-resolution immune profiles are associated with survival, relapse and graft-versus-host-disease after allogeneic hematopoietic cell transplantation.Bone marrow transplantation · 2026Article
- The Effect of Myeloid-Derived Suppressor Cells in Graft-versus-Host Disease.Journal of clinical practice and research · 2026Article
- Infused PMN-MDSCs from G-CSF-mobilized PBSCs protect against II-IV° acute graft-versus-host disease after allogeneic hematopoietic stem cell transplantation.BMC immunology · 2026Article
- Monocytic Cell Variations in Postallotransplant Environment: Balancing Graft Versus Host Disease and Graft-Versus-Leukemia Effect.Journal of immunology research · 2026Review
- Interleukin Networks in GVHD: Mechanistic Crosstalk, Therapeutic Targeting, and Emerging Paradigms.International journal of molecular sciences · 2025Review
- Cellular therapies for the prevention and treatment of acute graft-versus-host disease.Stem cells (Dayton, Ohio) · 2025Review
- Graft-Versus-Host Disease Mouse Models: A Clinical-Translational Perspective.Methods in molecular biology (Clifton, N.J.) · 2025Review
- Pathophysiology and preclinical relevance of experimental graft-versus-host disease in humanized mice.Biomarker research · 2024Review
- Article
- Perspectives for the Use of Umbilical Cord Blood in Transplantation and Beyond: Initiatives for an Advanced and Sustainable Public Banking Program in Greece.Journal of clinical medicine · 2024Article
- Myeloid-derived suppressor cells exhibit distinct characteristics in bone marrow and blood of individuals with diffuse large B-cell lymphoma.Frontiers in medicine · 2024Article
- Relapse of acute myeloid leukemia after allogeneic stem cell transplantation: immune escape mechanisms and current implications for therapy.Molecular cancer · 2023Review
- Article
- Acute graft-versus-host disease.Nature reviews. Disease primers · 2023Review
- A pan-cancer analysis of SLC1A5 in human cancers.Heliyon · 2023Article
- Posttransplantation cyclophosphamide expands functional myeloid-derived suppressor cells and indirectly influences Tregs.Blood advances · 2023Article
- Myeloid-derived suppressor cells: key immunosuppressive regulators and therapeutic targets in hematological malignancies.Biomarker research · 2023Review
- Graft-versus-Host Disease Modulation by Innate T Cells.International journal of molecular sciences · 2023Review
- Exosomes, MDSCs and Tregs: A new frontier for GVHD prevention and treatment.Frontiers in immunology · 2023Review
- Peripheral levels of monocytic myeloid-derived suppressive cells before and after first induction predict relapse and survivals in AML patients.Journal of cellular and molecular medicine · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
Abstract
backgroundMyeloid-derived suppressor cells (MDSCs) are implicated in the complex interplay involving graft-versus-leukemia (GVL) effects and graft-versus-host disease (GVHD) after allogeneic hematopoietic stem cell transplantation (allo-HCT) in hematologic malignancies.
methodsA review of literature through PubMed was undertaken to summarize the published evidence on the pathophysiology and clinical implications of MDSCs in allo-HCT. Literature sources published in English since 1978 were searched, using the terms Natural Suppressor (NS) cells, MDSCs, GVHD, and allo-HCT.
resultsIn vivo studies demonstrated that MDSCs derived from mobilization protocols could strongly suppress allo-responses mediated by T cells and enhance T-Reg activity, thus inhibiting GVHD toxicity. However, the influence of MDSCs on the GVL effect is not fully defined.
conclusionsThe induction or maintenance of MDSC suppressive function would be advantageous in suppressing inflammation associated with GVHD. Pathways involved in MDSC metabolism and the inflammasome signaling are a promising field of study to elucidate the function of MDSCs in the pathogenesis of GVHD and translate these findings to a clinical setting.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.